VIVORYON THERAPEUTICS NV (VVY.AS) Fundamental Analysis & Valuation

AMS:VVY • NL00150002Q7

Current stock price

1.315 EUR
-0.01 (-0.38%)
Last:

This VVY.AS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. VVY.AS Profitability Analysis

1.1 Basic Checks

  • VVY had negative earnings in the past year.
  • VVY had a negative operating cash flow in the past year.
  • In the past 5 years VVY always reported negative net income.
  • In the past 5 years VVY always reported negative operating cash flow.
VVY.AS Yearly Net Income VS EBIT VS OCF VS FCFVVY.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • VVY's Return On Assets of -194.47% is on the low side compared to the rest of the industry. VVY is outperformed by 86.08% of its industry peers.
  • VVY's Return On Equity of -392.42% is on the low side compared to the rest of the industry. VVY is outperformed by 64.56% of its industry peers.
Industry RankSector Rank
ROA -194.47%
ROE -392.42%
ROIC N/A
ROA(3y)-121.31%
ROA(5y)-94.21%
ROE(3y)-158.36%
ROE(5y)-122.89%
ROIC(3y)N/A
ROIC(5y)N/A
VVY.AS Yearly ROA, ROE, ROICVVY.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

  • VVY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VVY.AS Yearly Profit, Operating, Gross MarginsVVY.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. VVY.AS Health Analysis

2.1 Basic Checks

  • VVY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • VVY has about the same amout of shares outstanding than it did 1 year ago.
  • The number of shares outstanding for VVY has been increased compared to 5 years ago.
  • VVY has a worse debt/assets ratio than last year.
VVY.AS Yearly Shares OutstandingVVY.AS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
VVY.AS Yearly Total Debt VS Total AssetsVVY.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • VVY has an Altman-Z score of -36.67. This is a bad value and indicates that VVY is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of VVY (-36.67) is worse than 87.34% of its industry peers.
  • VVY has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of VVY (0.00) is better than 89.87% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -36.67
ROIC/WACCN/A
WACC7.43%
VVY.AS Yearly LT Debt VS Equity VS FCFVVY.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 4.04 indicates that VVY has no problem at all paying its short term obligations.
  • VVY has a better Current ratio (4.04) than 73.42% of its industry peers.
  • A Quick Ratio of 4.04 indicates that VVY has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 4.04, VVY is in the better half of the industry, outperforming 78.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.04
Quick Ratio 4.04
VVY.AS Yearly Current Assets VS Current LiabilitesVVY.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. VVY.AS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 60.00% over the past year.
  • The Revenue has grown by 100.00% in the past year. This is a very strong growth!
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.62%
Revenue 1Y (TTM)100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, VVY will show a very strong growth in Earnings Per Share. The EPS will grow by 121.74% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y50.14%
EPS Next 2Y19.63%
EPS Next 3Y8.87%
EPS Next 5Y121.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VVY.AS Yearly Revenue VS EstimatesVVY.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2021 2023 2029 2030 0 500M 1B 1.5B
VVY.AS Yearly EPS VS EstimatesVVY.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 20 30 40

More info and screens

Find the best growth stocksShow best growing peers

0

4. VVY.AS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VVY. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VVY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VVY.AS Price Earnings VS Forward Price EarningsVVY.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VVY.AS Per share dataVVY.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.63%
EPS Next 3Y8.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VVY.AS Dividend Analysis

5.1 Amount

  • VVY does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VVY.AS Fundamentals: All Metrics, Ratios and Statistics

VIVORYON THERAPEUTICS NV

AMS:VVY (4/9/2026, 10:34:14 AM)

1.315

-0.01 (-0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-04
Earnings (Next)04-27
Inst Owners8.28%
Inst Owner ChangeN/A
Ins Owners8.32%
Ins Owner ChangeN/A
Market Cap38.94M
Revenue(TTM)N/A
Net Income(TTM)-12.48M
Analysts85.71
Price Target5.95 (352.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)20.69%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)1.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.24
P/tB 16.57
EV/EBITDA N/A
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0
BVpS0.11
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -194.47%
ROE -392.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.31%
ROA(5y)-94.21%
ROE(3y)-158.36%
ROE(5y)-122.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.04
Quick Ratio 4.04
Altman-Z -36.67
F-Score2
WACC7.43%
ROIC/WACCN/A
Cap/Depr(3y)105.74%
Cap/Depr(5y)75.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.62%
EPS Next Y50.14%
EPS Next 2Y19.63%
EPS Next 3Y8.87%
EPS Next 5Y121.74%
Revenue 1Y (TTM)100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y60.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year52.68%
EBIT Next 3Y8.27%
EBIT Next 5YN/A
FCF growth 1Y67.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.04%
OCF growth 3YN/A
OCF growth 5YN/A

VIVORYON THERAPEUTICS NV / VVY.AS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of VIVORYON THERAPEUTICS NV (VVY.AS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VVY.AS.


What is the valuation status of VIVORYON THERAPEUTICS NV (VVY.AS) stock?

ChartMill assigns a valuation rating of 0 / 10 to VIVORYON THERAPEUTICS NV (VVY.AS). This can be considered as Overvalued.


What is the profitability of VVY stock?

VIVORYON THERAPEUTICS NV (VVY.AS) has a profitability rating of 0 / 10.


Can you provide the financial health for VVY stock?

The financial health rating of VIVORYON THERAPEUTICS NV (VVY.AS) is 4 / 10.


Can you provide the expected EPS growth for VVY stock?

The Earnings per Share (EPS) of VIVORYON THERAPEUTICS NV (VVY.AS) is expected to grow by 50.14% in the next year.